The effects of interleukin-2 (IL-2) and recombinant human thrombopoietin (rhTPO) on a basic carboplatin (GC) plus gemcitabine (GEM) treatment regimen in a murine lung carcinoma model was investigated with 50 nude mice with subcutaneous tumors derived from human lung cancer cells with intraperitoneal injection [55]. Here, IL2 is linked to lung carcinoma.